Is Pfizer's Oncology Division Poised to Grow?
With Pfizer's third-quarter results set to be released in late October, the best way for investors to prepare for the report is to review last quarter's results. The following video focuses on the Q2 results from the big pharma's oncology division. This division contributed only 3% to the company's top line, but sales grew 24% in the second quarter, and the company is developing a new cancer drug, palbociclib, which received the FDA's breakthrough designation this year. This is a competitive designation that other drug developers, such as Pharmacyclics and its partner Johnson & Johnson , have also benefited from. Analysts David Williamson and Max Macaluso discuss these therapeutics in the following video.
3 stocks to hold forever
Every good investor wants to build that perfect portfolio that he or she can set and forget forever. Fortunately, it's easier than anyone ever knew. We've uncovered the pillars of such a portfolio today, and we're willing to share The Motley Fool's 3 Stocks to Own Forever. Simply stated, we think they're the best stocks for true long-term investors to know about, and you can uncover them for free today, instantly; just click here now.
The article Is Pfizer's Oncology Division Poised to Grow? originally appeared on Fool.com.David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.